+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 1Year - 30Years
All Genders
ID07387926

Study of Asciminib with Chemotherapy and Blinatumomab in Children and Young Adults With Relapsed or Refractory Philadelphia-Positive or Ph-like Acute Lymphoblastic Leukemia

Led by Novartis Pharmaceuticals · Updated on 2026-10-15

50

Participants Needed

4

Research Sites

140 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of asciminib combined with chemotherapy in children and young adults aged 1 to 30 years who have relapsed or refractory Philadelphia chromosome-positive Ph or ABL-class Ph-like acute lymphoblastic leukemia ALL. This phase III, open-label, single-arm study includes participants with specific genetic leukemia types, except those with a known T315I mutation who are studied separately. The study aims to find a treatment regimen that may be more tolerable than traditional high-intensity chemotherapy. The study has two parts Part 1 focuses on dose escalation to determine the recommended phase 2 dose RP2D of asciminib with low intensity chemotherapy, while Part 2 evaluates the safety, tolerability, and efficacy of asciminib at the RP2D combined with blinatumomab. Treatment involves three cycles the first with asciminib plus low intensity chemotherapy, followed by two cycles of blinatumomab with asciminib. Various formulations and dosing schedules are used depending on age and mutation status. Participants will undergo core treatment phases followed by survival follow-up. Assessments include monitoring for dose-limiting toxicities, adverse events, complete remission rates, and minimal residual disease using specialized laboratory tests. Pharmacokinetics of asciminib are also measured. The study follows participants over several cycles of treatment and tracks outcomes such as disease-free and overall survival up to approximately three years.

CONDITIONS

Brief Title

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here